BRPI0915367B8 - peptídeo anti-p2x7 - Google Patents

peptídeo anti-p2x7

Info

Publication number
BRPI0915367B8
BRPI0915367B8 BRPI0915367A BRPI0915367A BRPI0915367B8 BR PI0915367 B8 BRPI0915367 B8 BR PI0915367B8 BR PI0915367 A BRPI0915367 A BR PI0915367A BR PI0915367 A BRPI0915367 A BR PI0915367A BR PI0915367 B8 BRPI0915367 B8 BR PI0915367B8
Authority
BR
Brazil
Prior art keywords
peptides
antibodies
epitope
cancer
peptide
Prior art date
Application number
BRPI0915367A
Other languages
English (en)
Portuguese (pt)
Inventor
Gidley-Baird Angus
Alexander Barden Julian
Original Assignee
Biosceptre International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2008903451A external-priority patent/AU2008903451A0/en
Application filed by Biosceptre International Ltd filed Critical Biosceptre International Ltd
Publication of BRPI0915367A2 publication Critical patent/BRPI0915367A2/pt
Publication of BRPI0915367B1 publication Critical patent/BRPI0915367B1/pt
Publication of BRPI0915367B8 publication Critical patent/BRPI0915367B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0915367A 2008-07-04 2009-07-03 peptídeo anti-p2x7 BRPI0915367B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2008903451A AU2008903451A0 (en) 2008-07-04 Composite peptide
AU2008903451 2008-07-04
PCT/AU2009/000869 WO2010000041A1 (en) 2008-07-04 2009-07-03 Anti- p2x7 peptides and epitopes

Publications (3)

Publication Number Publication Date
BRPI0915367A2 BRPI0915367A2 (pt) 2015-11-03
BRPI0915367B1 BRPI0915367B1 (pt) 2020-10-13
BRPI0915367B8 true BRPI0915367B8 (pt) 2021-05-25

Family

ID=41465424

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0915367A BRPI0915367B8 (pt) 2008-07-04 2009-07-03 peptídeo anti-p2x7

Country Status (12)

Country Link
US (3) US8597643B2 (enExample)
EP (1) EP2318438B1 (enExample)
JP (2) JP5701752B2 (enExample)
KR (1) KR101701300B1 (enExample)
CN (1) CN102143978B (enExample)
AU (1) AU2009266430B2 (enExample)
BR (1) BRPI0915367B8 (enExample)
CA (1) CA2729868C (enExample)
ES (1) ES2610225T3 (enExample)
IL (2) IL210220A (enExample)
NZ (1) NZ590146A (enExample)
WO (1) WO2010000041A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
ATE542139T1 (de) 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
JP5670192B2 (ja) * 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド 新規ｐ２ｘ７エピトープ
KR101701300B1 (ko) 2008-07-04 2017-02-01 바이오셉터 (어스트) 피티와이 엘티디 항­ｐ２ｘ７ 펩티드 및 에피토프
ES2904911T3 (es) 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
BR112012015561B1 (pt) 2009-12-24 2019-11-12 Biosceptre International Ltd anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy
JP6790062B2 (ja) * 2015-04-02 2020-11-25 バイオセプター・（ユーケー）・リミテッド 疼痛治療
KR20180043841A (ko) * 2015-09-11 2018-04-30 카리나 바이오테크 피티와이 엘티디 키메라 항원 수용체 및 이의 용도
WO2018071959A1 (en) 2016-10-21 2018-04-26 Biosceptre (Uk) Limited Cytotoxic particles
BR112023020659A2 (pt) * 2021-04-08 2023-12-05 Biosceptre Aust Pty Ltd Métodos para controlar a atividade de célula imune
JP2025531021A (ja) * 2022-09-14 2025-09-19 バイオセプター （オースト） プロプライエタリー・リミテッド 免疫細胞を検出する方法
CN120187747A (zh) * 2022-09-14 2025-06-20 生物权威(澳大利亚)有限责任公司 工程化免疫细胞的富集
JP2025531030A (ja) * 2022-09-14 2025-09-19 バイオセプター （オースト） プロプライエタリー・リミテッド 免疫細胞のインビボ検出

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE920765A1 (en) 1991-03-12 1992-09-23 Scripps Research Inst Cell surface receptors homologous to coagulation factors v¹and viii
EP0760850A1 (en) 1994-05-27 1997-03-12 Glaxo Group Limited P2x RECEPTORS (PURINOCEPTOR FAMILY)
EP0854923A2 (en) 1995-08-09 1998-07-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Isolated nucleic acid molecules useful as leukemia markers and in breast cancer prognosis
WO1997041222A1 (en) 1996-04-30 1997-11-06 Smithkline Beecham P.L.C. HUMAN P2x4 RECEPTOR SPLICE-VARIANTS
US6303338B1 (en) * 1996-08-16 2001-10-16 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6133434A (en) * 1997-04-28 2000-10-17 Glaxo Group Limited Purinergic receptor
US6329503B1 (en) * 1998-06-01 2001-12-11 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
EP1157038A4 (en) 1999-02-26 2005-01-19 Smithkline Beecham Corp CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
AUPP991199A0 (en) * 1999-04-21 1999-05-13 University Of Sydney, The Methods for diagnosing pre-cancerous and cancerous conditions
AU1339701A (en) 1999-10-22 2001-05-08 Lifespan Biosciences, Inc. Anti-cancer nucleic acid and protein targets
AU2001274902A1 (en) * 2000-12-06 2002-06-18 Linex Technologies, Inc. Efficient sharing of capacity by remote stations using circuit switching and packet switching
AUPR201500A0 (en) 2000-12-11 2001-01-11 Biosceptre Pty Ltd Methods for identifying pre-neoplastic and neoplastic states in mammals
DK1360203T3 (da) 2001-01-17 2009-04-20 Intreat Pty Ltd Antistoffer mod ikke-funktionel P2X7-receptordiagnose og behandling af cancerlidelser og andre tilstande
AU2002322192B2 (en) 2001-09-03 2008-05-01 Biosceptre International Limited Antibodies to non-functional P2X7receptor, diagnosis and treatment of cancers and other conditions
DK1473367T3 (da) 2003-04-17 2007-10-01 Affectis Pharmaceuticals Ag Midler og fremgangsmåder til diagnosticering og behandling af effektive lidelser
CA2607541A1 (en) * 2005-05-05 2006-12-28 Medicure International Inc. Inhibition of atp-mediated, p2x7 dependent pathways by pyridoxal-5-phosphaste and vitamin b6 related compounds
US7767789B2 (en) * 2005-06-02 2010-08-03 University Hopitals of Cleveland Truncated proteins as cancer markers
WO2007027957A2 (en) 2005-08-31 2007-03-08 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008043146A1 (en) 2006-10-10 2008-04-17 Biosceptre International Limited Antibodies against non functional p2x7 receptor
JP2010505426A (ja) * 2006-10-10 2010-02-25 バイオスセプター インターナショナル リミテッド 非機能性ｐ２ｘ７受容体に対する抗体を産生するハイブリドーマ
ATE542139T1 (de) * 2007-09-14 2012-02-15 Biosceptre Int Ltd Purinerge (p2x)-rezeptoren in extrazellulärer körperflüssigkeit
JP5670192B2 (ja) * 2007-09-14 2015-02-18 バイオセプター・インターナショナル・リミテッド 新規ｐ２ｘ７エピトープ
KR101701300B1 (ko) 2008-07-04 2017-02-01 바이오셉터 (어스트) 피티와이 엘티디 항­ｐ２ｘ７ 펩티드 및 에피토프
ES2904911T3 (es) * 2009-08-20 2022-04-06 Biosceptre Aust Pty Ltd Anticuerpos anti-receptor P2X7 y fragmentos de los mismos
BR112012015561B1 (pt) 2009-12-24 2019-11-12 Biosceptre International Ltd anticorpos dirigidos contra receptores p2x7 oligoméricos não funcionais
US8828944B2 (en) 2010-04-22 2014-09-09 Institut Gustave Roussy Compounds and uses thereof to induce an immunogenic cancer cell death in a subject
CN106310245A (zh) 2010-09-10 2017-01-11 生物权威(澳大利亚)有限责任公司 陪伴动物治疗
US9566318B2 (en) 2011-07-01 2017-02-14 Biosceptre (Aust) Pty Ltd Combination therapy

Also Published As

Publication number Publication date
JP5701752B2 (ja) 2015-04-15
US20110110959A1 (en) 2011-05-12
US20160199442A1 (en) 2016-07-14
ES2610225T3 (es) 2017-04-26
CN102143978B (zh) 2015-02-18
BRPI0915367B1 (pt) 2020-10-13
US9328155B2 (en) 2016-05-03
BRPI0915367A2 (pt) 2015-11-03
KR101701300B1 (ko) 2017-02-01
IL210220A (en) 2016-04-21
IL232394A0 (en) 2014-06-30
IL232394A (en) 2016-04-21
US8597643B2 (en) 2013-12-03
CN102143978A (zh) 2011-08-03
NZ590146A (en) 2012-09-28
US20140135475A1 (en) 2014-05-15
EP2318438A4 (en) 2012-11-21
CA2729868A1 (en) 2010-01-07
EP2318438A1 (en) 2011-05-11
WO2010000041A1 (en) 2010-01-07
IL210220A0 (en) 2011-03-31
AU2009266430A8 (en) 2011-03-10
EP2318438B1 (en) 2016-11-02
AU2009266430B2 (en) 2014-08-14
JP2015038144A (ja) 2015-02-26
CA2729868C (en) 2018-07-10
US10238716B2 (en) 2019-03-26
JP2011526249A (ja) 2011-10-06
KR20110031222A (ko) 2011-03-24
AU2009266430A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
BRPI0915367B8 (pt) peptídeo anti-p2x7
ES2560532T3 (es) Moléculas y métodos de modulación de la proteína 6 relacionada con el receptor de lipoproteína de baja densidad (LRP6)
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
ECSP13013102A (es) Dominios no inmunizados que se unen al suero y su uso para extender la vida media en el suero
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
CY1119854T1 (el) Ανθρωπινο μονοκλωνικο αντισωμα με ειδικοτητα για ε πρωτεϊνη ιου δαγκειου πυρετου οροτυπου 1 και χρησεις αυτου
MX2013007371A (es) Peptidos de enlace her2 radiomarcados.
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
BRPI0908496A2 (pt) inibição de angiogênese
PE20131376A1 (es) Anticuerpos para metaloproteinasa-9 de matriz
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
MX2021009793A (es) Constructos de anticuerpo para dll3 y cd3.
CL2014001297A1 (es) Anticuerpo multivalente que tiene al menos dos dominios de unión a receptores para dos diferentes sitios de unión de un receptor diana lrp6; anticuerpo aislado biparatopico que une lrp6; anticuerpo igg biparatópico; secuencia nucleotídica que los codifica; vector; composición farmacéutica que los comprende; y uso para tratar cáncer que exprese lrp6 (div. sol. n°3093-12).
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
BR112015020587A2 (pt) proteínas de fusão de apelina e suas utilizações
CY1118928T1 (el) Αντι-οχ40 αντισωματα και μεθοδοι χρησης τους
CO6630173A2 (es) Moléculas de unión a seroalbuminae
GT201200271A (es) Proteínas que se unen al tnf-a
CL2014000400A1 (es) Proteina de union al antigeno especifica para el heterodimero alfa4beta7; y composicion que la comprende (div.sol.n°2306-11).
CR20130609A (es) Eliminación de células diana por parte de células t citotóxicas específicas de virus utilizando complejos que comprenden mhc de clase 1
CO6351750A2 (es) Composiciones y métodos para anticuerpos que se dirigen a la proteina de complementos c5
UA113712C2 (xx) Антитіло до fap і способи його застосування
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
EA201792245A1 (ru) Биоконъюгаты и их применения
BR112013029409A8 (pt) produtos farmacêuticos de peptídeo melhorados para resistência à insulina

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 03/07/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF